undamentalytics Newsletter
Sign in

Aligos Therapeutics, Inc. cash flow statement

In fiscal 2025, Aligos Therapeutics, Inc.'s operations generated −$82.5m of cash; it spent $0 on capital projects, leaving free cash flow of −$82.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−74−116−79−79−81−83−94
Depreciation and amortisation3322111
Stock-based pay3131513856
Capital spending2110000
Free cash flow−76−117−80−79−81−83−94
Free cash flow after stock pay−79−130−95−92−89−88−100
Shares issued———0———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ALGS vs DYAIALGS vs DBVTALGS vs CAMPALGS vs XBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aligos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aligos Therapeutics, Inc.